Bobby_Sherpa
liked
With brother @Trytosaveabit
Scaling out is the practice of gradually reducing your position size as the trade moves in your favor, locking in profits while leaving a portion of your position active to potentially benefit from further gains.
Imagine you’re a trader who buys 1,000 shares of a stock at $100 per share, expecting it to rise. Your plan involves scaling out of the position as the price increases to secure profits and reduce risk.
1. Initial Purchase: You buy 1,000 sha...
Scaling out is the practice of gradually reducing your position size as the trade moves in your favor, locking in profits while leaving a portion of your position active to potentially benefit from further gains.
Imagine you’re a trader who buys 1,000 shares of a stock at $100 per share, expecting it to rise. Your plan involves scaling out of the position as the price increases to secure profits and reduce risk.
1. Initial Purchase: You buy 1,000 sha...
95
21
22
Bobby_Sherpa
liked
$GEE Group (JOB.US)$
Hope you caught my alert this morning! If you did you might have bought at .22! It ran to .50 for over 100% potential gains!
Hope you caught my alert this morning! If you did you might have bought at .22! It ran to .50 for over 100% potential gains!
4
6
$CNS Pharmaceuticals (CNSP.US)$ rebouncing?🧐
5
1
$CNS Pharmaceuticals (CNSP.US)$ is it ready to fly now?
1
$Crown LNG (CGBS.US)$ $3🤔???????
Translated
Bobby_Sherpa
reacted to
4
2
Bobby_Sherpa
liked
$Curis (CRIS.US)$
Combination therapies for the treatment of cancer
Patent number: 12178821
Abstract: The present disclosure relates to methods of treating certain diseases and disorders (e.g., cancer) with a combination of an IRAK4 inhibitor, a BCL-2 inhibitor, and a nucleoside analog.
Type: Grant
Filed: February 25, 2022
Date of Patent: December 31, 2024
Assignee: Curis, Inc.
Inventors: Reinhard von Roemeling, Andrey Ugolkov, Robert Martell
Combination therapies for the treatment of cancer
Patent number: 12178821
Abstract: The present disclosure relates to methods of treating certain diseases and disorders (e.g., cancer) with a combination of an IRAK4 inhibitor, a BCL-2 inhibitor, and a nucleoside analog.
Type: Grant
Filed: February 25, 2022
Date of Patent: December 31, 2024
Assignee: Curis, Inc.
Inventors: Reinhard von Roemeling, Andrey Ugolkov, Robert Martell
14
9
Bobby_Sherpa
liked
$Revelation Biosciences (REVB.US)$
hope you got my alert on Tuesday. Another nice and early alert with MASSIVE GAINS!!!!
hope you got my alert on Tuesday. Another nice and early alert with MASSIVE GAINS!!!!
4
3
Bobby_Sherpa
commented on
$Revelation Biosciences (REVB.US)$
making moves
making moves
5